p21 is a key regulator of the cell cycle and plays a complex role in cancer. It promotes cell cycle arrest in response to various stimuli and acts as a sensor and effector of anti-proliferative signals. While p21 is primarily known for its tumor suppressor function through p53-dependent pathways, it can also exhibit oncogenic activities under certain conditions. p21 inhibits cell cycle progression by binding to and inhibiting the kinase activity of CDK2 and CDK1, leading to growth arrest at specific cell cycle stages. It also interferes with PCNA-dependent DNA polymerase activity, thereby inhibiting DNA replication and modulating DNA repair processes. p21 regulates gene transcription by de-repressing p300-CREBBP, which is part of a positive feedback loop that amplifies p21 expression. It also inhibits apoptosis by promoting cell cycle inhibition, especially in response to genotoxic insults. However, p21 can also promote apoptosis through p53-dependent and p53-independent mechanisms under certain cellular stresses. p21 modulates DNA repair processes by inhibiting DNA synthesis and promoting DNA repair. It also plays a role in tumor suppression by repressing the transcription of genes involved in cell cycle progression and by activating gene transcription through p300-CREBBP. The transcriptional regulation of p21 is complex, with multiple transcription factors, ubiquitin ligases, and protein kinases involved in its regulation. p21 can be upregulated or downregulated in various cancers, and its expression can vary depending on the cellular context. p21 can act as a tumor suppressor or an oncogene, depending on the cellular environment. The post-transcriptional control of p21 is also important, with ubiquitin-dependent and ubiquitin-independent proteolysis playing a role in its stability and localization. The oncogenic activities of p21 are influenced by its ability to suppress apoptosis and promote the assembly of D-type cyclins with CDK4 and CDK6. p21 can also promote oncogenesis independently of its anti-apoptotic activity by promoting the assembly of cyclin D complexes with CDK4 or CDK6. The complex network regulating p21 activity and biological functions requires careful consideration in cancer therapy. Targeting p21 or factors regulating its activity for therapeutic intervention is a promising but challenging task. Advances in understanding the role of p21 in modulating DNA repair processes are needed to better understand its role in cancer development and treatment.p21 is a key regulator of the cell cycle and plays a complex role in cancer. It promotes cell cycle arrest in response to various stimuli and acts as a sensor and effector of anti-proliferative signals. While p21 is primarily known for its tumor suppressor function through p53-dependent pathways, it can also exhibit oncogenic activities under certain conditions. p21 inhibits cell cycle progression by binding to and inhibiting the kinase activity of CDK2 and CDK1, leading to growth arrest at specific cell cycle stages. It also interferes with PCNA-dependent DNA polymerase activity, thereby inhibiting DNA replication and modulating DNA repair processes. p21 regulates gene transcription by de-repressing p300-CREBBP, which is part of a positive feedback loop that amplifies p21 expression. It also inhibits apoptosis by promoting cell cycle inhibition, especially in response to genotoxic insults. However, p21 can also promote apoptosis through p53-dependent and p53-independent mechanisms under certain cellular stresses. p21 modulates DNA repair processes by inhibiting DNA synthesis and promoting DNA repair. It also plays a role in tumor suppression by repressing the transcription of genes involved in cell cycle progression and by activating gene transcription through p300-CREBBP. The transcriptional regulation of p21 is complex, with multiple transcription factors, ubiquitin ligases, and protein kinases involved in its regulation. p21 can be upregulated or downregulated in various cancers, and its expression can vary depending on the cellular context. p21 can act as a tumor suppressor or an oncogene, depending on the cellular environment. The post-transcriptional control of p21 is also important, with ubiquitin-dependent and ubiquitin-independent proteolysis playing a role in its stability and localization. The oncogenic activities of p21 are influenced by its ability to suppress apoptosis and promote the assembly of D-type cyclins with CDK4 and CDK6. p21 can also promote oncogenesis independently of its anti-apoptotic activity by promoting the assembly of cyclin D complexes with CDK4 or CDK6. The complex network regulating p21 activity and biological functions requires careful consideration in cancer therapy. Targeting p21 or factors regulating its activity for therapeutic intervention is a promising but challenging task. Advances in understanding the role of p21 in modulating DNA repair processes are needed to better understand its role in cancer development and treatment.